Dexcom Inc - DXCM STOCK NEWS

DexCom, Inc. (NASDAQ: DXCM) recently highlighted key research at the 81st American Diabetes Association (ADA) virtual conference (June 25-29, 2021). The data emphasizes the critical role of continuous glucose monitoring (CGM) in diabetes management across various populations. Notably, presentations included analyses on CGM's effects on hypoglycemia control, glycemic control improvements, and healthcare cost reductions among Type 2 diabetes patients. Additionally, the conference showcased over a dozen studies linking CGM to enhanced health outcomes and quality of life.

DexCom (NASDAQ:DXCM) has launched The Global Movement for Time in Range, a campaign aimed at enhancing awareness and adoption of time in range metrics in diabetes management. Co-led by Nick Jonas, the initiative is backed by various diabetes organizations, aiming to inform patients about time in range's benefits and improve healthcare strategies. Survey data indicates that many insulin-treated diabetes patients lack awareness of this crucial metric, highlighting a significant opportunity for education and improved healthcare practices. The movement seeks to address these knowledge gaps.

Dexcom and Tandem Diabetes Care support Canadian athlete Sébastien Sasseville in his 14-day cycling challenge across Canada to raise awareness for diabetes technology access. The endeavor aims to highlight disparities in access to continuous glucose monitoring (CGM) systems across provinces. Recent announcements regarding public coverage of CGM systems in Quebec, Saskatchewan, and British Columbia reflect progress, yet inequalities persist. Sasseville uses the t:slim X2 insulin pump and Dexcom G6 CGM to manage his type 1 diabetes during the ride.

Dexcom (NASDAQ: DXCM) announces expanded provincial coverage for the Dexcom G6 CGM System through BC PharmaCare for individuals aged two years and older on intensive insulin therapy. This initiative aims to enhance diabetes management, providing broader access to life-changing technology. Notable endorsements from medical professionals highlight the positive impact of CGM on glycemic control and reduction in emergency room visits due to severe hypoglycemia. BC now joins other provinces in Canada offering public coverage for CGM systems.

DexCom (Nasdaq: DXCM) has unveiled findings from two studies presented at the 14th International Conference on Advanced Technologies & Treatments for Diabetes. The MOBILE study indicates significant benefits of continuous glucose monitoring (CGM) for Type 2 diabetes patients using basal insulin. Key outcomes include increased time in optimal glucose range and significant A1c reduction. Additionally, new data on the Dexcom G7 shows promising sensor accuracy. These advancements highlight DexCom’s ongoing commitment to enhancing diabetes care.

DexCom (NASDAQ:DXCM) has announced an upcoming presentation at the William Blair 41st Annual Growth Stock Conference. Jereme Sylvain, Executive Vice President and CFO, will represent the company on June 1, 2021, at 12:00pm CDT. The presentation will be available via live webcast on the Dexcom Investor Relations website, where it will also be archived for future reference.

DexCom empowers individuals to manage diabetes through cutting-edge continuous glucose monitoring (CGM) technology, enhancing diabetes care globally.

DexCom reported a robust Q1 2021 with revenue of $505 million, up 25% year-over-year. U.S. revenue grew by 30% while international revenue rose by 10%. GAAP operating income reached $45.9 million (9.1% of revenue), an increase of 80 basis points from last year. Despite a decrease in non-GAAP operating margin, the company has expanded its U.S. sales force and launched a venture capital fund. DexCom has raised its 2021 revenue guidance to $2.26 - 2.36 billion, anticipating 17-22% growth.

DexCom, Inc. (NASDAQ:DXCM) will release its first quarter 2021 financial results on April 29, 2021, after market close. A conference call is scheduled for 4:30 p.m. (Eastern Time) the same day to discuss the results, which will also be available via webcast on the company's investor relations website. DexCom is recognized for its innovative continuous glucose monitoring (CGM) systems, aiming to enhance diabetes management worldwide.

DexCom, Inc. (NASDAQ: DXCM) has announced the promotion of Jereme Sylvain to Executive Vice President and Chief Financial Officer. Sylvain, who has over 20 years of experience in corporate finance, previously served as Senior Vice President, Finance and Chief Accounting Officer since March 2020. His new role includes overseeing the entire finance organization and supporting COO Quentin Blackford in scaling the business and corporate development efforts. CEO Kevin Sayer highlighted Sylvain's contributions to the finance team and the company's growth strategy.